The effect of renal and hepatic impairment and of spironolactone on digoxin immunoassays.
The effect of renal and/or hepatic dysfunction, and of concomitant spironolactone therapy, on seven commercial digoxin assays was evaluated in 45 patients taking both these drugs, and a comparison made with the digoxin concentrations measured using the same assays in 30 patients taking digoxin in the absence of spironolactone. The study showed that increasing renal dysfunction resulted in increasing inaccuracy in assay results with the methods tested. The influence of concomitant spironolactone was to produce a further distortion, which was shown to be additive in patients with impaired renal and/or liver function. The results highlight the unresolved specificity problems which persist in many, if not all, of the immunoassays currently offered to clinical laboratories which, if not recognised, could significantly influence digoxin therapy and patient management.
Morris
R G
RG
Department of Clinical Pharmacology, Queen Elizabeth Hospital, Adelaide, South Australia.
Frewin
D B
DB
Taylor
W B
WB
Glistak
M L
ML
Lehmann
D R
DR
D000368:Aged; D000369:Aged, 80 and over; D004077:Digoxin / Q000097:blood*; D005260:Female; D006801:Humans; D007118:Immunoassay; D007674:Kidney Diseases / Q000097:blood*; D008107:Liver Diseases / Q000097:blood*; D008297:Male; D008875:Middle Aged; D013148:Spironolactone / Q000494:pharmacology*
D013148:Spironolactone; D004077:Digoxin